<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41798">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827124</url>
  </required_header>
  <id_info>
    <org_study_id>Ain Shams U</org_study_id>
    <nct_id>NCT01827124</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial for Comparison Of Intravenous Carbeitocin Versus Oxytocin In Management Of Placental Delivery In Second Trimester Interruption</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wafaa Uthman Ahmed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous Carbetocin is more efficient than intravenous infusion oxytocin in management of
      placental delivery in 2nd trimester  interruption.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Record duration of spontaneous placental expulsion after delivery of fetus in second trimester interruption</measure>
    <time_frame>at the time of delivery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of blood loss in each group by weighing all pads put under the patient after delivery of fetus tell expulsion of placenta( before and after using of pads).</measure>
    <time_frame>at time of delivery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>CARBETOCIN FOR PREVENTION OF PLACENTAL RETAINED</condition>
  <arm_group>
    <arm_group_label>carbetocin and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100microgram carbetocin IV and 1cc normal saline(placebo)infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20Interntional unit oxytocin infusion and 1cc normal saline IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <arm_group_label>carbetocin and placebo</arm_group_label>
    <arm_group_label>oxytocin and placebo</arm_group_label>
    <other_name>pabal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <arm_group_label>carbetocin and placebo</arm_group_label>
    <arm_group_label>oxytocin and placebo</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:16-50 years

          -  Pregnancy duration: 14-24weeks

          -  Spontaneous abortion or medical induced abortion at 14-24weeks

        Exclusion Criteria:

          -  Age less than 16years and more than 50 years

          -  Surgical termination

          -  Placenta previa

          -  Uterine fibroid
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>WAFAA UTHMAN AHMED, M.B.CH.B</last_name>
    <phone>00201119760754</phone>
    <email>WAFAA.UTHMAN@YAHOO.COM</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams university maternity hospital department of obstetrics and gynacology</name>
      <address>
        <city>Cairo</city>
        <state>Tertiary</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Ibrahim , ass. prof</last_name>
      <phone>01223416828</phone>
      <phone_ext>002</phone_ext>
      <email>abugooda@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed SE El-safty 002, lecturer</last_name>
      <phone>01003922211</phone>
      <phone_ext>002</phone_ext>
      <email>melsafty76@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>WAFAA UT AHMED, M.B.CH.M</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>April 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Wafaa Uthman Ahmed</investigator_full_name>
    <investigator_title>Ain shams university</investigator_title>
  </responsible_party>
  <keyword>CARBETOCIN AND OXYTOCIN AND SECOND TRIMESTER INTERRUPTION</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
